CCM
SWTX

Consonance Capital Management’s SpringWorks Therapeutics SWTX Stock Holding History

Consonance Capital Management’s Portfolio SWTX Stock Details SWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-305,994
Closed -$19.4M – 17
2021
Q3 		$19.4M Sell
305,994
-893,345
-74% -$68.8M 10.63% 4
2021
Q2 		$98.8M Sell
1,199,339
-2,060
-0.2% -$156K 11.89% 2
2021
Q1 		$88.4M Buy
1,201,399
+307,900
+34% +$24.1M 9.42% 2
2020
Q4 		$64.8M Buy
893,499
+290,767
+48% +$18.7M 6.05% 7
2020
Q3 		$28.7M Buy
+602,732
New +$25.7M 3.5% 15

Other funds holding SWTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Consonance Capital Management's SWTX Position: Q4 2021 in Review

Consonance Capital Management sold out of SpringWorks Therapeutics (SWTX) in Q4 2021, closing a stake of 305,994 shares — an estimated $19.4M sold.

Consonance Capital Management first reported a position in SWTX in Q3 2020 and held it in 5 quarters. The position peaked at $98.8M in Q2 2021. 144 funds tracked by Wall St. Rank hold SWTX as of Q4 2021.

  • Consonance Capital Management reported no remaining SpringWorks Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Consonance Capital Management sold 305,994 SpringWorks Therapeutics shares in Q4 2021, an estimated $19.4M.
  • Consonance Capital Management first reported a position in SpringWorks Therapeutics in Q3 2020 and held it in 5 quarters.
  • Consonance Capital Management's SpringWorks Therapeutics position peaked at $98.8M in Q2 2021.
  • 144 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q4 2021.

Based on Consonance Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.